NCIRD Surveillance Systems

This interactive dashboard tracks emergency department visits for laboratory-confirmed severe acute respiratory coronavirus type 2 (SARS-CoV-2), influenza (flu), and respiratory syncytial virus (RSV).

This site comprises three platforms that conduct population-based surveillance for laboratory-confirmed hospitalizations associated with COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) among children and adults.

This site provides a combined view of emergency department visit data for multiple respiratory conditions as tracked by the National Syndromic Surveillance Program (NSSP).

This laboratory-based system monitors temporal and geographic circulation patterns of RSV, HPIV, HMPV, respiratory and enteric adenoviruses and rotavirus detections.

This passive, voluntary surveillance system monitors laboratory detections of enteroviruses and parechoviruses in the United States.

The Influenza Division at CDC collects, compiles, and analyzes information on influenza viruses and disease activity year-round in the United States.

CDC, the WHO collaborating center in Atlanta, conducts research and analysis on information and samples from around the world to monitor changes in influenza viruses with the aim of reducing influenza disease impact through the use of vaccines.

This laboratory- and population-based surveillance system for invasive bacterial pathogens provides an infrastructure for public health research.

Seven U.S. study sites focus on population-based surveillance and data collection on the use and impact of vaccines and the impact of vaccine policies.

Since HPV infections and related diseases are not nationally notifiable, CDC and partners have created a surveillance system to monitor the impact of HPV vaccine on HPV-related cervical disease.

CDC uses four primary networks to estimate influenza vaccine effectiveness. Monitoring the performance of influenza vaccines is important for understanding and improving the benefits of vaccine.